Global Phosphorous Acid & Phosphonate Derivatives Market Size, Share & Forecast 2026–2033

Scope: two merchant pools, and the four products this report does not count

The companion analysis published in this segment — Phosphorous Acid Is Priced by a Power Bill, Not a Rock Price — refused to publish a market size for this molecule, and the refusal was deliberate: technical phosphonates, phosphite crop treatments, specification-grade intermediates and the glyphosate-chain feedstock are four products with four customer bases and four qualification regimes, so a combined total would not carry a decision. This report does publish a number. The difference is the perimeter, not a change of mind.

Two pools are counted. The first is merchant phosphonates: HEDP, ATMP, PBTC, DTPMP, HDTMP and PAPEMP, together with their sodium salts and the standard 40–60 per cent solutions most of the volume ships in, sold as products to formulators, distributors and industrial accounts. The second is merchant phosphorous acid itself — H3PO3, technical and pure grades — sold as an acid or as a phosphite salt to buyers who do not make phosphonates.

Four things are excluded, and each exclusion is a decision rather than a gap. Captive phosphorous acid consumed inside glyphosate and other agrochemical synthesis is an intermediate transfer between two plants, often inside one company’s own fence line, and it is not a sale to a customer. Phosphite crop-protection products and phosphite fertilisers are an agrochemical and fertiliser business with a registration file, a distributor network and a seasonal demand curve that has nothing in common with a drum of scale inhibitor. Phosphate rock and wet-process phosphoric acid are a different molecule branch priced off a different index entirely. Phosphate esters and phosphite antioxidants used as polymer stabilisers are a different specification regime and a different buyer.

What survives is the only part of the phosphorus complex where every tonne is invoiced against a published number, which is what makes it priceable.

The number

Read the third row before the first. Value compounds at 5.78 per cent against 3.39 per cent for tonnage, so realised revenue per tonne rises from USD 1,552 to USD 1,864 — +20.11 per cent across eight years. That is the entire investment case and the entire risk in one line: this is not a volume market. It is a market where a tonne has to become worth more, because the supply of the feedstock behind it is not being expanded.

Three mechanisms carry the gap between the two rates, and only the first is comfortable. The mix moves from HEDP, the commoditised workhorse that the laundry aisle buys on price, toward PBTC and PAPEMP, which hold up under higher temperature and chlorine and are bought by power plant and desalination specification rather than by tender. The acid itself rises in real terms as the thermal branch tightens. And the phosphate value chain’s growth capital keeps going somewhere else entirely — which is the next section but one.

What the price actually is: five quotes, four bases, one molecule

There is no phosphorous acid index. There are quotes, and they disagree by more than most buyers realise.

On 1 August 2025 a Zibo producer quoted RMB 11,500 per tonne for 99 per cent crystal material ex-works and RMB 11,000 for 98.5 per cent — identical to its quote two months earlier, in June. In May a Henan producer quoted RMB 12,800 for the same 99 per cent grade. Over the same months, traders in Shandong and Jiangsu offered 99 per cent material at RMB 6,700 to 10,000, and 97–98 per cent at RMB 7,800 to 9,000. The distance between the highest traded offer and the lowest is 71.64 per cent of the low quote, on a specification that is nominally the same.

Downstream the confusion compounds, because two quotes for the same phosphonate can be 65.35 per cent apart and both be honest. HEDP was quoted at RMB 6,350 per tonne on a national-standard basis in Zaozhuang and RMB 10,500 at 90 per cent content in Hubei. Put them on an active tonne — divide by content — and the first becomes RMB 10,583 and the second RMB 11,667: the gap collapses to 10.24 per cent. Four-fifths of that 65 per cent spread is water, and a procurement team comparing the two headlines is comparing freight and dilution.

Now the part that matters for anyone modelling this market. Phosphorous acid is not an input to a phosphonate; it is most of the phosphonate.

Read the third row as a single sentence: 58 per cent of a tonne of HEDP is the yellow phosphorus inside it. The merchant phosphonate business is therefore, arithmetically, a conversion fee charged on an electrothermal commodity — and every participant in it is really trading the spread between a power price in two Chinese provinces and a specification document.

Three pools, and why the map is not the demand

The map is not the demand. Asia-Pacific holds 47 per cent of value because that is where the molecule is made and where both the detergent industry and the industrial water build-out sit, and because Chinese producers export at a cost advantage that European producers cannot match on a commodity grade. Europe holds 24 per cent on a much smaller tonnage, because Europe buys the registered, documented, audited version of the same molecule. A European tonne and an Asian tonne are not the same purchase even when the assay is identical, and the regional split is really a specification split wearing a geography.

The supply side: a furnace fleet nobody is funding

Every tonne in this market traces back to yellow phosphorus, and yellow phosphorus traces back to a furnace and a power contract. There is no commercial non-thermal route to phosphorous acid: the acid is made by hydrolysing phosphorus trichloride, and the trichloride comes from P4. Electrochemical reduction of phosphoric acid to phosphorous acid has been published for decades and has never scaled to a merchant plant. So the supply of the entire derivative tree is set by how much electricity is being thrown at phosphorus in Yunnan, Sichuan and Guizhou.

That fleet is not being expanded. In the week to 5 September 2025 Chinese thermal phosphoric acid output was about 18,900 tonnes at a 35.46 per cent operating rate, against purified wet-process acid at about 60,800 tonnes and 64.75 per cent. The monthly data says the same thing: in June 2025 thermal acid produced 87,600 tonnes at 38.39 per cent — 27.75 per cent of total phosphoric acid output — while the purified wet branch ran at 65.44 per cent. The thermal branch is running at roughly half the utilisation of the branch next door, and the branch next door is where the capital is going.

The reason is a cathode. Chinese output of power and other batteries reached 831.1 GWh in the first seven months of 2025, up 57.5 per cent year on year, and lithium iron phosphate chemistries were 656.4 GWh, or 78.98 per cent of it. LFP cathodes consume purified wet-process acid, not thermal acid, and iron phosphate plants were already running at 68.12 per cent. So the growth capital in phosphorus is bidding for high-grade rock — P2O5 at 30 per cent or above now carries a visible premium — while the furnace fleet that supplies every phosphonate in this report runs below 40 per cent and waits for a power price it likes better.

That is the structural constraint, and it is a strange one: the material is not scarce, the route to it is simply uncompetitive with the route to something else. A merchant buyer of phosphorous acid is therefore exposed to a capacity decision made by a battery supply chain, and the constraint will arrive before the price signal does, because nobody announces a plant they are not building.

Demand: the laundry aisle, not the cooling tower

The sector’s own disclosure locates the demand precisely, and it is not where the water-treatment narrative puts it. When PCBL agreed to buy Aquapharm Chemicals — described by its acquirer as the world’s number two in phosphonates — it set out the portfolio: phosphonates 53 per cent, oil and gas chemicals 25 per cent, polymers the rest, with a customer base named as Procter & Gamble, Unilever, Henkel and Reckitt.

Those are not cooling-tower accounts. The largest single outlet for merchant phosphonates in the world is the detergent aisle, where a phosphonate does the sequestering work that sodium tripolyphosphate used to do in the markets that restricted phosphorus in laundry detergents. Industrial water treatment — cooling, boiler, reverse osmosis, desalination — is the second outlet and the one with the better growth story. Oilfield scale squeeze is the third, and it is bought by specification and by service contract rather than by the drum.

The consequence for the forecast is direct. If the largest outlet is a mature consumer category competing on cost per wash, then the volume trend of this market belongs to a flat business, and the 3.39 per cent volume CAGR in this report is that fact expressed as a number. The growth in the value line is not the detergent aisle doing more; it is the specification end of the market paying more, and the acid getting dearer underneath both.

What the consolidation is paying for

Two transactions are moving at once, and between them they describe what this market is actually worth.

The first is done. PCBL signed a share purchase agreement in November 2023 to acquire Aquapharm for INR 3,800 crore, against revenue of INR 2,045 crore and projected EBITDA of INR 370 crore — 1.86 times sales and 10.3 times EBITDA, on a business reporting a 31 per cent gross margin and a 20 per cent EBITDA margin. The second is in exclusive talks: Dorf Ketal, advised against Bain Capital, negotiating to buy Italmatch Chemicals for USD 1.6 billion, reported in September 2025. Italmatch runs more than 20 manufacturing plants and eight R&D centres across 1,100 employees, with a declared Advanced Water Solutions business unit.

Here is the reading. A buyer paying 1.86 times sales for a business whose raw material is 58 per cent of its product price is not buying a molecule; the molecule is buyable at a published quote from any of a hundred Chinese producers. It is buying two things that are not: a qualified position on a consumer goods company’s approved-vendor list, and the formulation file that goes with it. That is why the multiples in this market sit closer to specialty chemicals than to commodity phosphorus, and why the ownership of the merchant tier is concentrating precisely as the feedstock behind it is being starved.

The counter-evidence, in the report and not the footnote

The best argument against this forecast comes from the largest listed pure-play on the Chinese side. Shandong Taihe Technologies reported revenue of RMB 2,358.4 million in 2024, up 6.93 per cent — recovered from RMB 2,205.6 million in 2023, which was itself a 19.12 per cent fall from RMB 2,727.0 million in 2022.

A merchant water-treatment chemical business does not lose a fifth of its revenue in one year because customers stopped treating water. It loses it because the price of the thing it sells fell, and because a pass-through chain gives back exactly what it was given. That is the shape of the risk here, and it is not hypothetical: it happened in 2023, in a thermal branch that was already under-used.

The margin arithmetic says the same thing in a different unit. On Aquapharm’s disclosed 31 per cent gross and 20 per cent EBITDA margin, an eleven-point spread carries the entire operating cost of the business. A 10 per cent move in yellow phosphorus is 5.8 points of HEDP revenue, which is 29 per cent of EBITDA if it is not passed through in the same quarter. Passing it through is a commercial capability, not a chemical one, and it is unevenly distributed.

Which is why the honest framing of the 20.11 per cent revenue-per-tonne assumption is this: it is not a claim that phosphonates become more valuable. It is a claim that the chain retains more of a rising feedstock price than it gave back of a falling one — and 2023 is the evidence that the retention is not automatic.

Companion research

Two adjacent questions sit underneath this one and are answered in separate reports. Global Surfactant Market covers the other half of the laundry-aisle formulation — USD 48.7 billion in 2025 to USD 72.9 billion by 2033 — and is the demand side this molecule is co-formulated with. Global Wastewater Treatment Market covers the plant that receives the outfall, which is where the total-phosphorus limit that constrains this molecule’s substitution actually binds.

The mechanism that prices the feedstock is set out in Phosphorous Acid Is Priced by a Power Bill, Not a Rock Price, and it is the argument this report is built on.

Competitive Landscape

Competitive landscape: concentrated at the top, infinitely fragmented underneath, and consolidating at exactly the wrong moment

The merchant tier is a handful of Western and Japanese specification suppliers, a small group of large Chinese and Indian producers with export reach, and a long tail of Chinese plants that compete on price for whatever grade the buyer will accept. The top of that structure is genuinely concentrated: Aquapharm, acquired by PCBL in 2023, was described by its buyer as the world’s number two in phosphonates, with 53 per cent of its portfolio in phosphonates and consumer goods companies as its named customers. Italmatch, in exclusive sale talks at USD 1.6 billion in 2025, runs over 20 plants and eight R&D centres with a dedicated Advanced Water Solutions unit.

Beneath them the structure changes character. Shandong Taihe Technologies — a listed Chinese producer of water treatment chemicals — reported RMB 2,358.4 million of revenue in 2024 across a portfolio that extends well beyond phosphonates, and the Chinese merchant base as a whole is large enough that no single plant can move the price. The top of this market is a brand-and-qualification oligopoly; the bottom is a spot market with a published quote that anybody can undercut by a few hundred renminbi and still make a conversion margin.

What competition actually turns on

Not on price per tonne, because the commodity end is already at the floor. It turns on three things. The first is approved-vendor status at a consumer goods company, which is worth more than a plant: a laundry formulation is validated against a specific phosphonate and a change of supplier requires re-validation of a product sold in hundreds of millions of units. The second is application engineering at the water end — the ability to send someone to a power station to diagnose a scaling problem, which is a service business attached to a chemical one and is why the industrial water majors defend the segment so hard. The third is supply security on a feedstock that is not being expanded, which increasingly means owning or contractually controlling acid rather than buying it in the merchant market.

The intensity is high and it is asymmetric. In a falling market — which 2023 was — the Chinese merchant base sets the clearing price and the Western specification producers defend share by accepting lower utilisation. In a rising market, which the feedstock arithmetic now implies, the specification producers with contracted acid pass through and keep their margin, while the merchant buyers of acid discover that the pass-through works in only one direction at a time.

Value Chain

Value chain: one furnace, one trichloride reactor, and a pass-through that looks like a specialty business

The chain has four steps and only the first one is hard. Yellow phosphorus comes out of an electric-arc furnace fed with phosphate rock, coke and silica at around 1,400 to 1,500 degrees Celsius, and the dominant input cost is electricity. That phosphorus is chlorinated to phosphorus trichloride, the trichloride is hydrolysed to phosphorous acid with the evolution of hydrogen chloride, and the acid is condensed with formaldehyde and either ammonia or a carbonyl compound to give the phosphonate.

Everything after the furnace is a reactor farm. A phosphonate plant is tanks, pumps, heat exchangers, scrubbers and a lot of effluent treatment; it is not capital-intensive in the way a furnace is, and it can be replicated in eighteen months by anyone who can buy the acid. That asymmetry explains the ownership pattern in this market better than any competitive analysis: the barrier is upstream and the value is downstream, so the downstream participants spend their capital buying customer lists rather than capacity.

Where the margin actually sits

Work the arithmetic on a tonne of HEDP. HEDP is 30.07 per cent phosphorus and phosphorous acid is 37.77 per cent, so a tonne of active HEDP carries 0.796 tonnes of acid. At a producer quote of RMB 11,000 per tonne that is RMB 8,758 of feedstock in a product quoted at RMB 10,500 as a 90 per cent solid — 75.07 per cent of the selling price. Against the 60 per cent solution at RMB 6,350, converted to an active basis of RMB 10,583, the same feedstock is 82.76 per cent.

Squeeze the same tonne one step further back. Yellow phosphorus at RMB 22,500 a tonne, at 0.301 tonnes of contained phosphorus per tonne of active HEDP, is RMB 6,766 — 58.0 per cent of the active tonne price. So the value the merchant tier adds, from acid to formulated product and documentation, is 25 per cent of the price at most and 17 per cent at the solution end. Everything else is a commodity pass-through with a service margin attached.

Distribution is where the spread lives

The published quotes show what that service margin looks like when it is unbundled. Producer ex-works quotes for 99 per cent crystal phosphorous acid ran at RMB 11,500 from a Zibo plant and RMB 12,800 from a Henan plant in 2025, while traders in the same provinces offered the same grade at RMB 6,700 to 10,000. That is a spread of 71.64 per cent between the lowest traded offer and the highest producer quote, and it exists because the trader is selling a different bundle: a pallet rather than a container, next week rather than next month, with the paperwork the buyer does not want to do. The producer is selling tonnes; the trader is selling availability.

For anyone modelling this market, the implication is that realised price and quoted price are different variables, and the difference moves with freight, packaging and payment terms rather than with supply and demand. A buyer who benchmarks a contract to a producer quote and then buys from a distributor is measuring the wrong number, and this is the single most common error in procurement of this molecule.

Investment Activity

Investment: cheap to build, expensive to enter, and being bought for the customer list

Capital intensity in the derivative step is medium at most. A phosphonate plant is a reactor farm with effluent treatment, and the constraint on building one is permits and effluent consents rather than capital. The genuinely capital-intensive asset in the chain is upstream: a yellow phosphorus furnace with its power contract, and the chlorine supply that goes with it. That asymmetry sets the investment logic of the whole sector, and it is why the money moving through this market is buying companies rather than building plants.

Two transactions define the current cycle. PCBL paid INR 3,800 crore for Aquapharm against revenue of INR 2,045 crore and projected EBITDA of INR 370 crore — 1.86 times sales, 10.3 times EBITDA. Dorf Ketal entered exclusive talks in September 2025 to acquire Italmatch Chemicals from Bain Capital for a reported USD 1.6 billion. Both buyers are consolidating a specialty platform, and neither is buying capacity: PCBL bought a phosphorus molecule alongside its carbon black franchise, and Dorf Ketal is buying water treatment and oilfield chemistry to bolt onto a hydrocarbon chemicals business.

What the multiple is paying for

At 1.86 times sales for a business where the raw material is 58 per cent of the product price, the buyer is explicitly not paying for the molecule. The molecule is available from a hundred plants at a published quote. What is not available is a validated position on a consumer goods company’s formulation, and the file that supports it. That is the asset being bought, and it explains why the multiple sits where it does rather than at a commodity chemical multiple, and why the seller can hold out for a strategic price.

The trend is rising, and the direction is one-way. As the acid tightens and the merchant spot market becomes a less reliable input, ownership of the customer relationship becomes the only defensible position in the chain — which means further consolidation of the top tier is the base case, not a possibility. An exit at the smaller end looks like a strategic sale to a water treatment platform rather than an IPO: the revenue base is too small for public markets and the customer list is too valuable to a strategic to be sold anywhere else.

Technology & Innovation

Technology: a mature molecule with no route around the furnace, and that is the finding

The chemistry in this market was settled between the 1960s and the 1980s and has barely moved since. ATMP is made by the Mannich reaction of phosphorous acid, formaldehyde and ammonium chloride. HEDP is made from phosphorous acid and acetic acid derivatives. PBTC adds a butane tricarboxylic backbone for thermal stability and chlorine tolerance. DTPMP and HDTMP extend the amine. There is no patent cliff, no generational product cycle and no proprietary catalyst that changes the cost curve, which is why the sector consolidates on customer relationships rather than on technology.

The one innovation that is genuinely absent

The absence is upstream. Every commercial route to phosphorous acid runs through phosphorus trichloride, and every commercial route to phosphorus trichloride runs through yellow phosphorus from an electrothermal furnace. The obvious alternative — electrochemical or catalytic reduction of phosphoric acid to phosphorous acid — has been in the literature for decades and has never reached merchant scale, because the energy penalty of the reduction step is comparable to the energy already spent making white phosphorus, and because the product would then have to compete with a route that already has the plant built.

That single missing technology is what makes this market’s supply curve vertical. In a normal specialty chemical market, a 74 per cent raw-material share in the selling price would attract substitution: a different feedstock, a different route, a bio-based alternative. Here there is none, and so the raw-material share is not a margin problem to be engineered away. It is a structural transfer of value from the derivative maker back to whoever owns the furnace and the power contract.

What is actually being innovated

Three things, and all of them are formulation rather than synthesis. The first is the shift from HEDP to PBTC and PAPEMP where operating temperature, chlorine dose or iron loading defeats the workhorse molecule — a switch that raises the price per tonne and narrows the customer list to the specification-driven end of the market. The second is the blend: phosphonates are increasingly sold inside a package with polyacrylate or maleic copolymers, which reduces the phosphonate dose per cubic metre and therefore reduces the tonnage sold per unit of water treated — a genuine volume headwind that the value line in this report absorbs.

The third is the least glamorous and possibly the most valuable: solids handling. Most phosphonate volume ships as a 40 to 60 per cent aqueous solution, which means a buyer is paying freight for water. The producers who have invested in high-content solids and in the crystallisation of phosphorous acid sell a materially cheaper tonne delivered, and the 65.35 per cent gap between a 60 per cent solution quote and a 90 per cent solid quote in the same market is that freight and water being priced. Anyone who standardises on an active-tonne basis is buying a better product than someone comparing headline prices, and the marketing of “high concentration” in this sector is really a marketing of logistics.

Market Risk

Market risk: four ways this forecast is wrong, and the one I would watch

The forecast is USD 855.0 million in 2025 growing 5.78 per cent to USD 1,340.0 million in 2033, on volume growth of 3.39 per cent. Four things would break it, and they are not equally likely.

Risk one: the pass-through inverts, as it did in 2023

This is the risk that matters most because it has already happened once. Shandong Taihe’s revenue fell 19.12 per cent from RMB 2,727.0 million in 2022 to RMB 2,205.6 million in 2023, in a year when the volume of water being treated did not fall by a fifth. The merchant chain gave back its price in a single year. If yellow phosphorus softens — and it does soften whenever the power tariff in Yunnan and Sichuan falls, which is exactly what drove the June 2025 decline in the yellow phosphorus quotation — the 20.11 per cent revenue-per-tonne assumption in this report becomes a 10 per cent decline, and the value CAGR goes negative while the volume CAGR is unchanged.

Risk two: substitution at the outfall

Phosphonates are 58 per cent yellow phosphorus by value and 100 per cent phosphorus by function, and a total-phosphorus consent at a wastewater plant does not distinguish between a nutrient and a scale inhibitor. The substitution vector is polyacrylate and maleic copolymer chemistry, which does the dispersant work without the phosphorus and is already the default in the tightest European consents. If low-phosphorus programmes accelerate in Asia — where the largest volume sits — the volume line of this forecast is the first casualty, and the value line follows with a lag.

Risk three: the volume denominator is a construction, and I say so

No customs line isolates phosphonates, and no industry association counts them. The 551.0 thousand tonne base is built from two pools: a phosphonate pool derived from a disclosed revenue base divided by a realised price band, and a merchant-acid pool derived from acid sold to non-phosphonate buyers. The band around that base is roughly plus or minus 15 per cent, and the value per tonne moves inversely with it. A reader who wants a measured global tonnage for this category should treat this one as a model with a stated construction, not a measurement.

Risk four: the detergent channel is one customer decision away from a reformulation

The largest single outlet for merchant phosphonates is laundry. A consumer goods company reformulating a single brand across one region can move more tonnage than a new water treatment contract adds in a year, and those reformulations are driven by cost per wash, packaging claims and retailer specifications rather than by anything in this report. Meanwhile the blend trend — selling phosphonate inside a polymer package — reduces the dose per cubic metre of water treated, which is a quiet structural headwind to tonnage that no price forecast captures.

The indicator I would watch is not the phosphonate price. It is the thermal phosphoric acid operating rate: if it moves above roughly 50 per cent, the supply constraint at the centre of this report is easing, and the revenue-per-tonne assumption is the first thing that should be revisited.

Regulatory Landscape

Regulatory: the critical-mineral designation protects a branch this market does not use

In November 2025 the U.S. Geological Survey published the 2025 List of Critical Minerals: sixty commodities, ten of them new. Phosphate is on it. The stated reason is worth quoting in substance rather than in paraphrase — the designation was recommended by the U.S. Department of Agriculture because phosphate is essential for U.S. agriculture.

That is a fertiliser argument, and it is the clearest available illustration of this report’s central asymmetry. A critical-mineral designation attaches to the rock and to the acid made from it for nutrient use. Phosphorous acid, phosphonates and phosphites do not come from that branch. They come from yellow phosphorus, an electrothermal product whose economics are set by a power tariff, and nothing in the critical-minerals framework — in the United States or anywhere else examined for this report — protects a furnace or discounts the electricity that runs it.

So the policy conversation about phosphorus and the commercial reality of this market are pointed in opposite directions. Every instrument that has been built to secure phosphorus supply — the critical-mineral listing, export controls on phosphate fertiliser, the premium now attached to P2O5 at 30 per cent and above — raises the cost and strategic importance of the wet branch. None of them touches the thermal branch, which is the only source of the molecule in this report, and which is running below 40 per cent utilisation because it cannot compete for capital against a lithium iron phosphate cathode.

The constraint that does bind

The regulatory variable that actually moves demand for this market is not product registration. It is the total-phosphorus limit at the outfall. A phosphonate is a scale inhibitor performing a legitimate industrial function, but at a wastewater treatment plant it is measured as phosphorus, and where a total-P discharge consent binds, the operator’s cheapest compliance route is to reduce phosphorus input rather than to upgrade the plant. That is the mechanism behind every low-phosphorus cooling programme in Europe and North America, and it is the only substitution vector in this market with a regulatory engine behind it.

No jurisdiction examined for this report restricts phosphonates as a product class. The exposure is indirect, discharge-side and local, and it is unevenly distributed — which is why the regional split in this report is really a specification split, with Europe carrying the tightest consent limits and therefore the highest average price per tonne and the most polymer substitution.